Compare RNW & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | EVO |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United Kingdom | Germany |
| Employees | 4336 | 4553 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | RNW | EVO |
|---|---|---|
| Price | $6.24 | $2.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.4M | 39.3K |
| Earning Date | 06-15-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $11.50 | $10.05 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $2.10 |
| 52 Week High | $8.24 | $4.42 |
| Indicator | RNW | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 23.24 |
| Support Level | $5.20 | N/A |
| Resistance Level | $6.56 | $3.36 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 68.14 | 4.39 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.